Clinical Trials Browser

Phase 1/2 × Stomach Neoplasms × Mesna × Clear all

NCT05207722 2024-12-12

CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Phase 1/2 Terminated

Gastrointestinal

Stomach Neoplasms